About Jecure Therapeutics
Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure’s academic founder is Dr. Ariel Feldstein, Division Chief of Gastroenterology at UCSD School of Medicine and a leading physician-scientist in hepatology. With operations in the biotech hub of San Diego, California, Jecure combines emerging NASH biology from Dr. Feldstein’s lab with an elite discovery team of veteran pharma/biotech scientists. Jecure’s lead program has identified small molecule inhibitors of a novel target and pro-inflammatory driver of NASH. Jecure is backed by top-tier life science investor Versant Ventures.
Leveraging over a decade of liver disease platform development with discovery programs informed by unique models of NASH and fibrosis.
First-in-class NASH and fibrosis company directly targeting the inflammasome and on track to be in the clinic in 2019.
Proven drug discovery leadership partnered with a pioneering NASH academic with $20 million committed from Versant Ventures.